BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27756439)

  • 1. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
    Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
    Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
    J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
    Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
    J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
    Robertson S; Acs B; Lippert M; Hartman J
    Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
    Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
    Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Pharoah PD; Caldas C
    Br J Cancer; 2012 May; 106(11):1798-806. PubMed ID: 22538974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.
    Johansson ALV; Trewin CB; Fredriksson I; Reinertsen KV; Russnes H; Ursin G
    Breast Cancer Res; 2021 Feb; 23(1):17. PubMed ID: 33526044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
    Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
    Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
    Abubakar M; Figueroa J; Ali HR; Blows F; Lissowska J; Caldas C; Easton DF; Sherman ME; Garcia-Closas M; Dowsett M; Pharoah PD
    Mod Pathol; 2019 Sep; 32(9):1244-1256. PubMed ID: 30976105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
    Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.
    Millar EK; Graham PH; McNeil CM; Browne L; O'Toole SA; Boulghourjian A; Kearsley JH; Papadatos G; Delaney G; Fox C; Nasser E; Capp A; Sutherland RL
    Br J Cancer; 2011 Jul; 105(2):272-80. PubMed ID: 21712826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
    Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
    BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.
    Zhang GC; Qian XK; Guo ZB; Ren CY; Yao M; Li XR; Wang K; Zu J; Liao N
    Med Oncol; 2012 Dec; 29(5):3222-31. PubMed ID: 22547076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer.
    Teleki I; Krenacs T; Szasz MA; Kulka J; Wichmann B; Leo C; Papassotiropoulos B; Riemenschnitter C; Moch H; Varga Z
    BMC Cancer; 2013 Feb; 13():50. PubMed ID: 23374644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.